VRTX VERTEX PHARMACEUTICALS INC Dividend Policy Changes 8-K Filing 2025 - Impairment Charge On March 28, 2025, Vertex Pharmaceuticals announced that its VX-264 diabetes treatment will not proceed further in development, leading to an expected non-cash impairment charge of about $400 million for 2025. The results of this impairment analysis will be disclosed in their upcoming quarterly report.Get access to all SEC 8-K filings of the VERTEX PHARMACEUTICALS INC